TG Therapeutics | TGTX - Loan Capital


TG Therapeutics reported $745.39M in Loan Capital for its fiscal quarter ending in June of 2026.





Loan Capital Change Date
AbbVie USD 64.53B 5.59B Mar/2026
Alaunos Therapeutics USD 4.47M 5.85M Jun/2022
Amgen USD 51.86B 27M Jun/2026
Ardelyx USD 203.52M 683K Mar/2026
Arrowhead Research USD 824.07M 401.34M Jun/2026
Bayer EUR 31.16B 480M Jun/2026
Biogen USD 7.29B 1B Jun/2026
Curis USD 29.43M 10.69M Jun/2024
Gilead Sciences USD 20.86B 1.27B Mar/2026
J&J USD 37.34B 183M Jun/2026
Karyopharm Therapeutics USD 264.49M 13.73M Mar/2026
Novartis USD 37.49B 42M Jun/2026
Novavax USD 246.3M 200K Dec/2025
PTC Therapeutics USD 535.52M 248.58M Jun/2026
Puma Biotechnology USD 10.87M 222K Jun/2025
Regeneron Pharmaceuticals USD 1.99B 400K Jun/2026
Roche Holding CHF 25.22B 2.21B Jun/2026
TG Therapeutics USD 745.39M 247K Jun/2026
Verastem USD 76.87M 4.46M Mar/2026
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025